Fibrotic interstitial lung diseases and air pollution: a systematic literature review.

Air Pollution Humans Idiopathic Pulmonary Fibrosis / epidemiology Lung Diseases, Interstitial / epidemiology

Journal

European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391

Informations de publication

Date de publication:
30 Sep 2020
Historique:
received: 27 04 2020
accepted: 04 05 2020
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 24 7 2021
Statut: epublish

Résumé

Air pollution is hypothesised to be a risk factor for interstitial lung diseases (ILD). This study systematically reviewed the literature regarding the impact of air pollution on idiopathic pulmonary fibrosis (IPF) and fibrotic interstitial lung diseases (ILD). A computer-assisted literature search of electronic databases was performed to identify studies focused on the association between ILDs and air pollution. Other inclusion criteria required that the article had to be: 1) original; 2) a prospective or retrospective study; and 3) fully published in English. Both randomised clinical trials and observational studies were considered. Only seven studies met the inclusion criteria. All studies investigated the relationship between pollution and IPF, except one that dealt with the relationship between pollution and hypersensitivity pneumonitis. Outcome measures included exacerbation of IPF, mortality, disease severity, prevalence of hypersensitivity pneumonitis, progression and incidence of IPF. On the whole, air pollution levels were negatively associated with outcomes in patients with IPF and fibrotic ILD outcome. The heterogeneity in the measurement and reporting of the end-points limited the performance of a quantitative synthesis of data. This systematic review provides supporting evidence linking exposure to air pollution to poor outcomes in patients with IPF and fibrotic ILD.

Sections du résumé

BACKGROUND BACKGROUND
Air pollution is hypothesised to be a risk factor for interstitial lung diseases (ILD). This study systematically reviewed the literature regarding the impact of air pollution on idiopathic pulmonary fibrosis (IPF) and fibrotic interstitial lung diseases (ILD).
METHODS METHODS
A computer-assisted literature search of electronic databases was performed to identify studies focused on the association between ILDs and air pollution. Other inclusion criteria required that the article had to be: 1) original; 2) a prospective or retrospective study; and 3) fully published in English. Both randomised clinical trials and observational studies were considered.
RESULTS RESULTS
Only seven studies met the inclusion criteria. All studies investigated the relationship between pollution and IPF, except one that dealt with the relationship between pollution and hypersensitivity pneumonitis. Outcome measures included exacerbation of IPF, mortality, disease severity, prevalence of hypersensitivity pneumonitis, progression and incidence of IPF. On the whole, air pollution levels were negatively associated with outcomes in patients with IPF and fibrotic ILD outcome. The heterogeneity in the measurement and reporting of the end-points limited the performance of a quantitative synthesis of data.
CONCLUSIONS CONCLUSIONS
This systematic review provides supporting evidence linking exposure to air pollution to poor outcomes in patients with IPF and fibrotic ILD.

Identifiants

DOI: 10.1183/16000617.0093-2020 PMID: 32817115 PMC: PMC9488644
pubmed: 32817115
pii: 29/157/200093
doi: 10.1183/16000617.0093-2020
pmc: PMC9488644
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: S. Harari reports grants and personal fees from Roche, outside the submitted work. Conflict of interest: G. Raghu has nothing to disclose. Conflict of interest: A. Caminati reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Cruciani has nothing to disclose. Conflict of interest: M. Franchini has nothing to disclose. Conflict of interest: P. Mannucci has nothing to disclose.

Références

Curr Opin Pulm Med. 2015 Mar;21(2):193-200
pubmed: 25621562
Semin Respir Crit Care Med. 2006 Dec;27(6):574-80
pubmed: 17195134
Thorax. 2014 Jul;69(7):660-5
pubmed: 24706041
Semin Respir Crit Care Med. 2008 Dec;29(6):670-9
pubmed: 19221965
Am J Epidemiol. 2000 Aug 15;152(4):307-15
pubmed: 10968375
Eur Respir J. 2014 Sep;44(3):744-53
pubmed: 24558178
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Environ Health Perspect. 2014 Apr;122(4):397-403
pubmed: 24518036
Chest. 2018 Jul;154(1):119-125
pubmed: 29355549
Environ Health Perspect. 2013 Jul;121(7):804-10
pubmed: 23632126
Int J Occup Environ Health. 2008 Apr-Jun;14(2):117-23
pubmed: 18507288
Eur Respir J. 2019 Jan 31;53(2):
pubmed: 30464015
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1374-81
pubmed: 21980033
Eur Respir J. 2018 Jan 25;51(1):
pubmed: 29371377
Eur Respir J. 2014 Apr;43(4):1124-31
pubmed: 24176998
Clin Rev Allergy Immunol. 2013 Dec;45(3):314-30
pubmed: 24242359
JAMA. 2006 Mar 8;295(10):1127-34
pubmed: 16522832
Lancet Respir Med. 2018 Jun;6(6):421-430
pubmed: 29650407
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 28100554
Thorax. 2012 Jan;67(1):6-11
pubmed: 21890573
Respirology. 2016 Jan;21(1):57-64
pubmed: 26138798
Chest. 2018 May;153(5):1221-1228
pubmed: 28802694
JAMA. 2002 Mar 6;287(9):1132-41
pubmed: 11879110
Epigenomics. 2012 Apr;4(2):195-203
pubmed: 22449190
Environ Health Perspect. 2009 Aug;117(8):1302-8
pubmed: 19672412
Eur Respir J. 2019 Feb 21;53(2):
pubmed: 30487201
Eur Respir J. 2017 Dec 7;50(6):
pubmed: 29217611
Eur Respir Rev. 2013 Sep 1;22(129):376-81
pubmed: 23997064
PLoS One. 2015 Sep 18;10(9):e0138146
pubmed: 26382947
Thorax. 2018 Feb;73(2):145-150
pubmed: 28798214
Lancet. 2019 Dec 14;394(10215):2198-2200
pubmed: 31761449
Epidemiology. 2014 Jan;25(1):48-57
pubmed: 24240657
Eur Respir J. 2014 Jul;44(1):66-77
pubmed: 24603814
Circulation. 2007 Jul 31;116(5):489-96
pubmed: 17638927
Int J Clin Exp Med. 2009 May 31;2(2):114-30
pubmed: 19684885
Lancet. 2014 May 3;383(9928):1581-92
pubmed: 24792855
Eur Respir J. 2019 Jul 25;54(1):
pubmed: 31285306
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753

Auteurs

Sergio Harari (S)

U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Milan, Italy.
Dept of Medical Sciences, San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy.
Dept of Clinical Sciences and Community Health, Università degli Studi di, Milan, Italy.
Both authors contributed equally.
ORCID: 0000-0001-8629-7391

Ganesh Raghu (G)

Center for Interstitial Lung Diseases, Dept of Medicine, University of Washington, Seattle, WA, USA.
Both authors contributed equally.

Antonella Caminati (A)

U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Milan, Italy lafitta@libero.it.

Mario Cruciani (M)

Italian National Blood Centre, National Institute of Health, Rome, Italy.
Infection Control Committee and Antibiotic Stewardship Programme, AULSS9 Scaligera, Verona, Italy.

Massimo Franchini (M)

Italian National Blood Centre, National Institute of Health, Rome, Italy.
Dept of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.

Piermannuccio Mannucci (P)

Scientific Direction, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Pollution de l'environnement › Pollution de l'air › Fibrotic interstitial lung diseases and air...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fibrotic interstitial lung diseases and air...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Fibrose pulmonaire idiopathique › Fibrotic interstitial lung diseases and air...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Fibrotic interstitial lung diseases and air...